NCT05520749View on ClinicalTrials.gov

Efficacy and Safety of Luspatercept: a Study by Fondazione Italiana Sindromi Mielodisplastiche

CompletedOBSERVATIONAL
Enrollment

215

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

January 31, 2023

Conditions
Myeloid Dysplasia
Interventions
DRUG

Luspatercept

Luspatercept treatment in adults with transfusion-dependent anaemia due to MDS

Trial Locations (1)

20089

Istituto Clinico Humanitas, Milan

All Listed Sponsors
collaborator

Istituto Clinico Humanitas

OTHER

lead

Fondazione Italiana Sindromi Mielodisplastiche-ETS

OTHER

NCT05520749 - Efficacy and Safety of Luspatercept: a Study by Fondazione Italiana Sindromi Mielodisplastiche | Biotech Hunter | Biotech Hunter